Network Prominence, Bargaining Power, and the Allocation of Value Capture Rights in Alliance Contracts
36 Pages Posted: 27 Aug 2013 Last revised: 10 Sep 2016
Date Written: August 27, 2013
Abstract
We suggest and provide empirical evidence that the bargaining power of alliance partners stemming from their prominence in alliance networks influences the ex-ante allocation of value capturing rights in high-tech alliance contracts. Network prominence can enhance the availability of alternative partners for a firm, and thereby elevates the firm’s bargaining power and enables the firm to receive i) more value capturing rights vis-à-vis its partner (i.e., more net value capturing rights) and ii) more rights to the unexpected outcomes vis-à-vis its partner. We empirically investigate the content of R&D collaboration contracts between biotech and pharmaceutical firms and show that as the prominence of the client (i.e., pharmaceutical firm) increases, it is able to attain i) more net value capturing rights to outcomes within the area of collaboration and ii) more rights to unexpected outcomes. By contrast, increased prominence of the R&D firm (i.e., biotech firm) decreases both the number of net value capturing rights the client receives as well as the rights to unexpected outcomes that the client captures in an alliance contract. The bargaining power that the R&D firm attains from its prominent position in alliance networks becomes less important during hot IPO markets, which provide the R&D firm more outside options to obtain financial resources. Hence, our paper documents that firms’ network positions can be an important source of bargaining power, contributing to the literature on strategic alliances, bargaining, and contract design.
Keywords: network prominence, bargaining power, entrepreneurial firms, alliance contracts, contract complexity, value capturing rights, incomplete contracts
JEL Classification: L14, L24, L10, L20, L65, D23
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
By Ilan Guedj and David S. Scharfstein
-
By Ilan Guedj and David S. Scharfstein
-
Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
By Sean Nicholson, Patricia M. Danzon, ...
-
Financial Contracting in Biotech Strategic Alliances
By David T. Robinson and Toby Stuart
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
By Patricia M. Danzon, Sean Nicholson, ...